Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesOmeros Corporation

Omeros Corporation

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
17.48 USD 0.56 ( 3.31%)
Last update at 2026-11-09T15:40:00Z
VOLUME
177482
Market Cap
1242.91M
P/E
10.41

Momentum Score

…

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
16.66
Low
17.61
High
52 Week Price Range
4.05
Low
19.65
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
16.92
Dividend Yield
-
Revenue TTM
38.42M
Revenue Per Share
0.55
Gross Profit TTM
14.73M
Debt / Equity
-1.97
ROE
-576.33%
Net Debt
229.48M
ROCE
-1.13%
Diluted EPS TTM
1.65

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -2.80M -182.63M -174.92M -182.03M -191.55M
Net income -3.35M -156.81M -117.81M 28.78M 194.24M
Selling general administrative 41.50M 49.73M 49.66M 50.67M 54.84M
Gross profit - -0.95M -69.78M - 0.00M
Reconciled depreciation 0.96M 0.95M 0.88M 0.95M 1.39M
Ebit -2.80M -157.95M -144.08M -163.39M -173.62M
Ebitda -1.83M -157.00M -143.16M -159.33M -171.88M
Depreciation and amortization 0.96M 0.95M 0.92M 4.06M 1.74M
Non operating income net other - - - 4.06M 1.74M
Operating income -122.80M -169.26M -164.53M -163.39M -173.62M
Other operating expenses 122.80M 169.26M 164.53M 163.39M 173.62M
Interest expense 0.96M 24.68M 30.84M 22.70M 19.67M
Tax provision 2.01M 2.31M 0.00M 0.00M 0.00M
Interest income 5.06M 11.30M 14.91M 4.06M -
Net interest income 5.06M -13.37M -16.78M -18.64M -19.67M
Income tax expense 2.01M 25.81M -57.11M -210.81M -365.76M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 122.80M 169.26M 164.53M 163.39M 173.62M
Cost of revenue - 0.95M 69.78M - 0.00M
Total other income expense net 120.00M -13.37M -10.39M -18.64M -17.93M
Discontinued operations - - - 229.45M 385.78M
Net income from continuing ops -4.81M -182.63M -181.68M -182.03M -191.55M
Net income applicable to common shares - - - 47.42M 194.24M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 325.63M 277.08M 378.27M 590.97M 419.27M
Other current assets 7.59M 7.17M 8.58M 6.30M 8.15M
Total liab 446.86M 459.69M 403.25M 505.29M 395.49M
Total stockholder equity -121.23M -182.61M -24.98M 85.68M 23.78M
Other current liab 47.46M 46.65M 31.87M 32.00M 33.13M
Common stock 0.72M 0.58M 0.61M 721.40M 0.63M
Capital stock 0.72M 0.58M - 0.63M 0.63M
Retained earnings -913.70M -910.35M -753.53M -635.72M -683.13M
Other liab - - - 0.44M 1.11M
Other assets - - - 124.48M 141.37M
Cash 9.66M 3.40M 7.11M 11.01M 100.81M
Total current liabilities 78.06M 79.53M 53.32M 136.68M 51.79M
Current deferred revenue 2.47M - - - -
Net debt 229.48M 203.62M 354.48M 331.01M 247.03M
Short term debt 23.36M 26.97M 13.74M 98.69M 5.25M
Short long term debt 17.06M 21.00M - 94.38M -
Short long term debt total 239.14M 207.02M 361.58M 342.02M 347.84M
Other stockholder equity 791.75M 727.16M 727.94M 720.77M 706.29M
Property plant equipment - - - 23.25M 30.01M
Total current assets 215.67M 134.12M 217.90M 443.24M 247.89M
Net tangible assets - - - 233.24M 52.91M
Short term investments 162.14M 86.73M 164.74M 183.91M 56.46M
Net receivables 36.27M 36.82M 37.47M 242.02M 82.47M
Long term debt 208.53M 166.58M - 220.91M 313.46M
Accounts payable 4.76M 5.91M 7.71M 5.99M 13.40M
Accumulated other comprehensive income - - 0.00M - -
Common stock total equity - - - 0.63M 0.63M
Retained earnings total equity - - - -635.72M -683.13M
Non currrent assets other 97.49M 125.32M 139.79M 124.48M 141.37M
Non current assets total 109.97M 142.96M 160.37M 147.73M 171.38M
Capital lease obligations 13.54M 19.44M - 26.74M 34.38M
Long term debt total - - - 220.91M 313.46M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -75.41M 82.22M -197.28M -127.45M 67.99M
Change to liabilities - - - -10.66M 15.31M
Total cashflows from investing activities 164.52M 82.22M 27.45M -127.56M 193.71M
Net borrowings -89.16M -41.34M -101.58M 0.04M 0.29M
Total cash from financing activities -42.17M 62.88M -106.08M 124.25M 6.32M
Change to operating activities - - - 66.76M 5.57M
Net income -3.35M -156.81M -117.81M 47.42M 194.24M
Change in cash 6.26M -3.71M -3.90M -89.80M 90.31M
Begin period cash flow 3.40M 7.11M 11.01M 100.81M 10.50M
End period cash flow 9.66M 3.40M 7.11M 11.01M 100.81M
Total cash from operating activities -116.09M -148.80M 74.73M -86.48M -109.72M
Issuance of capital stock 39.34M 0.00M 0.00M 0.00M 0.00M
Depreciation 0.96M 0.95M 0.92M 0.95M 1.39M
Other cashflows from investing activities 240.00M - - - 125.99M
Change to inventory - - - - 34.31M
Change to account receivables 30.45M 40.01M 245.72M -175.07M -34.31M
Sale purchase of stock 0.00M -11.85M -4.65M 0.41M 8.14M
Other cashflows from financing activities -42.17M 116.07M 0.15M 125.00M 8.14M
Change to netincome - - - 14.07M -292.93M
Capital expenditures 0.07M 0.17M 0.43M 0.11M 0.28M
Change receivables - - - -175.07M -34.31M
Cash flows other operating - - - 34.98M 4.90M
Cash and cash equivalents changes - - - -89.80M 90.31M
Change in working capital 33.72M 29.74M 247.42M -118.97M -14.11M
Stock based compensation 8.19M 10.49M 11.65M 14.07M 17.63M
Other non cash items -155.62M -33.17M -67.45M -29.96M 1.70M
Free cash flow -116.16M -148.97M 74.30M -86.60M -110.00M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
OMER
Omeros Corporation		 0.56
3.31%		 17.48 10.41 72.99 32.35 8.44 33.07 135.92
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Omeros Corporation

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

The Omeros Building, Seattle, WA, United States, 98119

206 676 5000

https://www.omeros.com

175

Name Title Year Born
Dr. Gregory A. Demopulos M.D. Co-Founder, Chairman, CEO & Pres 1959
Mr. Michael A. Jacobsen Chief Accounting Officer, VP of Fin. & Treasurer 1958
Mr. Peter B. Cancelmo J.D. VP, Gen. Counsel & Corp. Sec. 1979
Dr. Pamela Pierce Palmer M.D., Ph.D. Co-Founder 1963
Dr. George A. Gaitanaris M.D., Ph.D. Chief Scientific Officer & VP of Science 1957
Mr. Peter W. Williams VP of HR 1968
Dr. J. Steven Whitaker J.D., M.D. VP of Clinical Devel. & Chief Medical Officer 1956
Dr. Catherine A. Melfi Ph.D. Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems 1959
Ms. Nadia Dac VP & Chief Commercial Officer 1970
Ms. Debra K. Bowes M.T Chief Bus. Devel. Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.63%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.18%

  • Financial Services

    +1.33%

  • Healthcare

    +1.49%

  • Industrials

    +2.99%

  • Real Estate

    +0.41%

  • Technology

    +1.45%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…